Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
Status:
Recruiting
Trial end date:
2026-02-15
Target enrollment:
Participant gender:
Summary
This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed
and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell
lung cancer. The study will focus on the efficacy of two alternative staggered dosing
regimens.